durvalumab

Ligand id: 7985

Name: durvalumab

References
1. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017)
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Sci Rep7 (1): 5532. [PMID:28717238]
2. Queva C, Morrow M, Hammond S, Alimzhanov M, Babcock J, Foltz I, Kang JS, Sekirov L, Boyle M, Chodorge M. (2011)
Targeted binding agents against b7-h1.
Patent number: WO2011066389. Assignee: Medimmmune, Limited, Astrazeneca Ab, Amgen British Columbia, Medimmune, Llc. Priority date: 24/11/2009. Publication date: 03/06/2011.